The UK government is reportedly considering a financial aid package to encourage AstraZeneca to invest in an expansion of its vaccines manufacturing facility in Speke, near Liverpool. The UK ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...
LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...
The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio, including Augmentin, Ceftum, and T-Bact, strengthened their market ...
- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results